Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last --
Change Today 0.00 / 0.00%
Volume 0.0
1349 On Other Exchanges
Symbol
Exchange
1349 is not on other exchanges.
All times are local (Market data is delayed by at least 15 minutes).

shanghai fudan-zhangjiang-h (1349) Snapshot

Open
--
Previous Close
--
Day High
--
Day Low
--
52 Week High
-- - --
52 Week Low
-- - --
Market Cap
--
Average Volume 10 Days
0.0
EPS TTM
--
Shares Outstanding
0.0
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for SHANGHAI FUDAN-ZHANGJIANG-H (1349)

Related News

No related news articles were found.

shanghai fudan-zhangjiang-h (1349) Related Businessweek News

No Related Businessweek News Found

shanghai fudan-zhangjiang-h (1349) Details

Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd., together with its subsidiaries, researches, develops, and sells bio-pharmaceutical products in the People’s Republic of China. The company offers genetic engineering drugs, which include recombinant tissue type plasminogen activator for heart infarction; recombinant human lymphotoxin a-derivatives that has completed Phase II clinical trials for tumors; recombinant human tumor necrosis recipient Fc fusion protein (Etanercept) and high bio-activity recombinant human TNF receptor for arthritis; PTH that has completed Phase I clinical trials for osteoporosis; CD30-MMAE and Avastin, which are in pre-clinical study for tumors; Anti-sclerostin mab that is in pre-clinical study for Osteoporosis; and PCSK9 that is in pre-clinical study for hypercholesterolemia. It also provides photodynamic therapy drugs comprising Hemoporfin for port wine stain; Duteroporphyrin, a Phase II clinical trial product for tumors; Aminolevulinic acid that is in Phase II clinical trial for cervical diseases infected by HPV; and Aminolevulinic acid that has submitted for clinical trials, as well as is in pre-clinical study for treating brain gliomas and basal cell carcinoma diseases. In addition, the company offers liposomal drugs, including Libod, a doxorubicin liposome injection for tumors; Vincristine sulphate liposome that has completed Phase–I clinical trials for tumors; Nanoparticle Albumin-bound Paclitaxel that is in pre-clinical study for tumors; and Xenon liposome, which is in pre-clinical study for strokes. Further, it provides Antenatal Screening Diagnostic Reagent for down’s syndrome, etc. Additionally, the company offers research and development of pharmaceutical projects, medical instruments, medical diagnostic products, and biological and medical technology. It has a strategic agreement with Shanghai Pharmaceutical Co., Ltd. The company was founded in 1996 and is based in Shanghai, the People's Republic of China.

512 Employees
Last Reported Date: 08/20/15
Founded in 1996

shanghai fudan-zhangjiang-h (1349) Top Compensated Officers

Co-Founder, Chairman, General Manager and Cha...
Total Annual Compensation: CNY2.0M
Co-Founder, Deputy General Manager and Execut...
Total Annual Compensation: CNY1.3M
Deputy General Manager and Executive Director
Total Annual Compensation: CNY1.3M
Compensation as of Fiscal Year 2014.

shanghai fudan-zhangjiang-h (1349) Key Developments

Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co. Ltd. Reports Unaudited Consolidated Cash Flow and Capital Expenditure Results for the Six Months Ended June 30, 2015

Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co. Ltd. reported unaudited consolidated cash flow and capital expenditure results for the six months ended June 30, 2015. For the six months, net cash generated from operating activities was RMB 19,403,000 compared to RMB 738,000 a year ago. Purchase of property, plant and equipment was RMB 21,485,000 compared to RMB 27,985,000 a year ago.

Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co. Ltd. Reports Unaudited Consolidated Earnings Results for the Six Months Ended June 30, 2015

Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co. Ltd. reported unaudited consolidated earnings results for the six months ended June 30, 2015. For the six months, the company’s revenue was RMB 214,224,000 against RMB 153,370,000 a year ago. Operating profit was RMB 45,026,000 against RMB 41,371,000 a year ago. Profit before income tax was RMB 42,306,000 against RMB 40,314,000 a year ago. Profit for the period was RMB 37,168,000 against RMB 35,280,000 a year ago. Total comprehensive income for the period attributable to shareholders of the company was RMB 39,661,000 or RMB 0.0430 basic and diluted per share against RMB 36,296,000 or RMB 0.0393 basic and diluted per share a year ago.

Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co. Ltd. Announces Establishment of Derma Clinic Investment Co., Ltd

Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co. Ltd. announced that on 27 July 2015, Derma Clinic Investment Co. Ltd. was established in Shanghai, China. The company has received the approval, and completed the registration and filing procedures with the relevant authorities. The details of Derma Clinic are registered capital is RMB 50,000,000. Scope of business is Medical investment management, health industry management, project investment, assets management, investment consultation, business consultation, medical consultation and corporate management consultation.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
1349:HK $6.24 HKD -0.13

1349 Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for 1349.
View Industry Companies
 

Industry Analysis

1349

Industry Average

Valuation 1349 Industry Range
Price/Earnings 39.0x
Price/Sales 8.9x
Price/Book 7.4x
Price/Cash Flow 39.0x
TEV/Sales 7.7x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact SHANGHAI FUDAN-ZHANGJIANG-H, please visit www.fd-zj.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.